KalVista Pharmaceuticals Inc 2025年季度报告

(Mark One)xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934. For the quarterly period endedJuly 31,2025OR oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934.For the transition period fromto.Commission File No.001-36830 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) 857-999-0075(Registrant’s telephone number, including area code) Former name, former address and former fiscal year, if changed since last report Securities registered pursuant to Section 12(b) of the Exchange Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.YESx NOo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).YES x NO o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filero Accelerated fileroSmaller reportingcompanyxEmerging growthcompanyo Non-accelerated filerx If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YESoNOx As of August 29, 2025, the registrant had50,523,274shares of common stock, $0.001 par value per share, issued andoutstanding. Table of Contents PART I. FINANCIAL INFORMATION Item 1.Financial Statements (unaudited)3Condensed Consolidated Balance Sheets3Condensed Consolidated Statements of Operations and Comprehensive Loss4Condensed Consolidated Statements of Changes in Stockholders’ Equity5Condensed Consolidated Statements of Cash Flows6Notes to the Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations16Item 3.Quantitative and Qualitative Disclosures About Market Risk20Item 4.Controls and Procedures20PART II. OTHER INFORMATIONItem 1.Legal Proceedings21Item 1A.Risk Factors21Item 2.Unregistered Sales of Equity Securities and Use of Proceeds21Item 3.Defaults Upon Senior Securities21Item 4.Mine Safety Disclosures21Item 5.Other Information21Item 6.Exhibits22Signatures23 KalVista Pharmaceuticals, Inc.Condensed Consolidated Balance Sheets(in thousands, except share and per share amounts) KalVista Pharmaceuticals, Inc.Condensed Consolidated Statements of Operations and Comprehensive Loss(in thousands, except share and per share amounts)(Unaudited) KalVista Pharmaceuticals, Inc.Condensed Consolidated Statement of Changes in Stockholders’ Equity(in thousands, except share amounts)(Unaudited) KalVista Pharmaceuticals, Inc.Condensed Consolidated Statements of Cash Flows(in thousands)(Unaudited) 1.The Company KalVista Pharmaceuticals, Inc. (“KalVista” or the “Company”) is a global biopharmaceutical company dedicated todeveloping and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet need. TheCompany has used its capabilities to develop sebetralstat, a novel, orally delivered, small molecule plasma kallikrein inhibitortargeting the disease hereditary angioedema (“HAE”). On July 3, 2025, the U.S. Food and Drug Administration (the “FDA”) approved EKTERLY®(sebetralstat) for thetreatment of acute attacks of HAE in adult and pediatric patients aged 12 years and older. The FDA approval was based on datafrom the phase 3 KONFIDENT clinical trial, published in the New England Journal of Medicine. Prior to the approval ofEKTERLY, all on-demand treatment options approved in the U.S. required intravenous or subcutaneous administration, whichcarries a significant treatment burden. Even with the use of long-term prophylaxis, most people living with HAE continue to haveunpredictable attacks and require ready access to on-demand medication. The Company’s headquarters is located in Framingham, Massachusetts, with additional offices and research activitieslocated in Cambridge, Massachusetts; Porton Down, United Kingdom; Salt Lake City, Utah; Zug, Switzerland; Tokyo, Japan;Berlin, Germany and Dublin, Ireland. Liquidity The C